Inflammation Is the Next Frontier in Fighting Heart Disease

Cardiovascular disease remains the leading cause of death globally, yet even patients with well-controlled LDL cholesterol face substantial residual risk of heart attack and stroke. This invited review by Spindler, Libby, and Ridker—published in Immunological Reviews in 2026—synthesizes decades of mechanistic and clinical evidence to argue that chronic vascular inflammation is a primary, actionable driver of atherosclerotic events, not merely a secondary consequence of lipid accumulation.

The authors detail how both innate and adaptive immune arms contribute to every stage of atherosclerosis. Macrophages engulf oxidized LDL to form foam cells and activate the NLRP3 inflammasome, triggering release of IL-1β—a master cytokine that amplifies local and systemic inflammation. IL-6, downstream of IL-1β, drives hepatic synthesis of C-reactive protein and other acute-phase reactants. T helper cells, regulatory T cells, and cytotoxic T cells further modulate plaque stability. IL-18, an inflammasome product, also emerges as a notable mediator of plaque vulnerability and adverse outcomes.

A critical clinical concept advanced in the review is 'residual inflammatory risk,' quantified by elevated high-sensitivity CRP (hsCRP) in patients already on guideline-directed lipid-lowering therapy. The authors argue that hsCRP above 2 mg/L signals ongoing inflammatory activity that predicts future cardiovascular events independently of LDL, supporting its routine use in risk stratification. The landmark CANTOS trial demonstrated that canakinumab, a monoclonal antibody targeting IL-1β, significantly reduced recurrent cardiovascular events in post-MI patients with elevated hsCRP, providing the first proof-of-concept that anti-inflammatory therapy—without lipid lowering—reduces hard cardiac endpoints. Importantly, responders who achieved the greatest hsCRP reduction derived the most benefit.

Low-dose colchicine, a generic anti-inflammatory that disrupts microtubule-dependent inflammasome assembly and neutrophil function, has also demonstrated cardiovascular event reduction in the COLCOT and LoDoCo2 trials, offering an accessible, cost-effective option. In contrast, broad immunosuppressive approaches and some earlier anti-inflammatory strategies failed, emphasizing that pathway specificity and patient selection are paramount. The review then surveys an emerging pipeline: ziltivekimab (an IL-6 ligand inhibitor) showed striking hsCRP and fibrinogen reductions in the RESCUE trial among CKD patients; NLRP3 inhibitors (e.g., colchicine analogs, novel small molecules) are in active development; and low-dose IL-2, which selectively expands regulatory T cells to dampen vascular inflammation, represents a biologically elegant immunomodulatory approach.

The authors stress that precision patient selection—enrolling individuals with demonstrably elevated inflammatory biomarkers—will be essential to maximizing therapeutic benefit while minimizing infection risk and other immunosuppressive side effects. They also note that atherosclerosis-related inflammation may intersect with clonal hematopoiesis of indeterminate potential (CHIP), cancer risk modulation observed in CANTOS, and inflammaging more broadly, connecting cardiovascular anti-inflammatory strategies to the wider field of longevity medicine.